Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.87 |
| ▸ | MEN1 | O00255 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.73 |
| ▸ | METAP2 | P50579 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.70 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.70 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.70 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11266259 | 0.98 | ALDH1A1 (0.83) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL11266257 | 0.98 | ALDH1A1 (0.83) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL1991348 | 0.93 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL45299 | 0.93 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL1991352 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL9853958 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL29024967 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL18784684 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL16634926 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AHPGDTP53 | |
| SCHEMBL1533636 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AHPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114481448-A | Nanofiber membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-24 | — | — | US | claimed |
| EP-2826480-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | Boehringer Ingelheim International GmbH (DE) | 2015-01-21 | — | — | EP | claimed |
| EP-2124951-B1 | 5-CYAN0-4- (PYRROLO[2, 3B]PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2014-05-21 | — | — | EP | claimed |
| US-20140057898-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | claimed |
| US-8247421-B2 | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | claimed |
| EP-2409705-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-25 | — | — | EP | claimed |
| EP-2361626-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-31 | — | — | EP | claimed |
| EP-2359829-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-24 | — | — | EP | claimed |
| US-20110171289-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | US | claimed |
| US-7223851-B2 | Nucleic acid-binding polymers | GENERAL DYNAMICS ADVANCED INFORMATION SYSTEMS, INC. (US) | 2007-05-29 | — | — | US | claimed |
| JP-2006524634-A | — | — | 2006-11-02 | — | — | JP | claimed |
| CN-1780627-A | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or vascular proliferation | BOEHRINGER INGELHEIM INT (DE) | 2006-05-31 | — | — | CN | claimed |
| US-20060058311-A1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | US | claimed |
| WO-2006018182-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| EP-1622619-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| US-20040157217-A1 | Nucleic acid-binding polymers | VERIDIAN SYSTEMS DIVISION | 2004-08-12 | — | — | US | claimed |
| US-4405678-A | Protected vapor-deposited metal layers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1983-09-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057898-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | ALDH1A1 2021/4885MEN1 820/4885KMT2A 4330/4885 |
| US-20110171289-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | ALDH1A1 2021/4885MEN1 820/4885KMT2A 4330/4885 |
| US-20060058311-A1 | Combinations for the treatment of diseases involving cell proliferation | CCNA1, MKI67, CCNA2 | ALDH1A1 1053/4885MEN1 231/4885KMT2A 3566/4885 |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | ALDH1A1 2021/4885MEN1 820/4885KMT2A 4330/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | ALDH1A1 2154/4885MEN1 759/4885KMT2A 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.